Today's Rundown Top 10 drug launch disasters Alexa is finding a voice in healthcare. Cedars-Sinai, Boston Children's sign on for new Amazon smart hospital service Biden admin infuses $560M more to buttress COVID-19 testing supply chain EMA starts rolling review of Merck's molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data Erytech shifts focus to leukemia as lead drug flunks late-stage pancreatic cancer trial Microsoft integrates healthcare cloud service with Cerner EHR for smoother telehealth visits Guardant’s liquid biopsy detects 96% of early-stage colorectal cancer cases with a single blood draw: study Novartis looks for silver lining in $2B canakinumab repurposing after 2nd lung cancer failure AstraZeneca veteran takes up CEO post at Medivir, becoming 4th person to hold the post in quick succession Doomed Next Gen ACO program saved Medicare $637M last year What would Medicare price negotiations bring to the US? Look to Europe, Lilly CEO Ricks says Roche, Foundation Medicine start global launch of cancer genomic profiling kit for labs worldwide Featured Story | By Angus Liu An estimated 40% of drugs approved between 2004 and 2016 underperformed, according to Wall Street’s prelaunch sales forecasts. That's a lousy track record, given that a strong launch is critical to a drug's success. Here, we list 10 drug launches from the past five years that suffered the most noteworthy failures. read more |
| |
|---|
|
Top Stories By Heather Landi Amazon launched a new service for hospitals that will embed its voice technology deeper into clinical settings at scale. As part of Alexa Smart Properties, the service will simplify how hospitals deploy and manage Alexa-enabled devices. An Amazon executive said the new service is just the tip of the iceberg for using ambient technology in healthcare. read more By Emmy Lucas In a continued effort to improve the availability of COVID-19 tests, the U.S. government is making its third investment in less than two months. This time, the focus is on shoring up the supply chain of materials needed to make the diagnostic kits and perform the tests including at-home tests. read more By Nick Paul Taylor Merck has opened another front in its campaign to get molnupiravir to market, kicking off a process that could lead to the approval of the oral COVID-19 antiviral in the European Union. read more By Annalee Armstrong After seeing an overall survival benefit in a mid-stage study of eryaspase in pancreatic cancer, Erytech Pharma likely thought a phase 3 would be in the bag. But the results are out and the phase 3 trial did not confirm the earlier result. read more By Rebecca Torrence Microsoft's Cloud for Healthcare service, announced in October 2020, will now allow providers to schedule and conduct virtual visits using Cerner's EHR directly through Microsoft's patient portal. read more By Andrea Park Guardant's Lunar-2 liquid biopsy test is designed to catch colorectal cancer in its earliest stages and requires only a standard blood draw, offering a less invasive and time-consuming alternative to the current standards for screening. read more By Angus Liu Is autoinflammatory disease treatment Ilaris a potential new therapy for non-small cell lung cancer? After two pivotal trial failures, the answer seems to be no, but Novartis is still seeing a glimmer of hope. read more By Nick Paul Taylor And the next person to hold the CEO post at Medivir is … Jens Lindberg. The AstraZeneca veteran will become the fourth person to hold the post, on an interim or permanent basis, in quick succession when he takes up the position. read more By Robert King A new study shows Next Gen ACOs collectively saved Medicare $637 million in 2020. CMS has decided not to continue the program after this year. read more By Kevin Dunleavy In an interview, Eli Lilly CEO and PhRMA chairman David Ricks warns that if Congress adopts changes to Medicare to negotiate drug prices, the pharma industry in the U.S. would start to resemble the landscape in Europe, where investment and innovation is stunted. read more By Andrea Park In their first joint offering since Roche bought out the sequencing company in 2018, Roche and its Foundation Medicine subsidiary are launching the Avenio Tumor Tissue CGP kit to labs in Europe, Asia and the Americas. read more |
